-+ 0.00%
-+ 0.00%
-+ 0.00%

Maxim Group Maintains Buy on Lucid Diagnostics, Lowers Price Target to $2

Benzinga·05/15/2026 19:55:00
Listen to the news
Maxim Group analyst Anthony Vendetti maintains Lucid Diagnostics (NASDAQ:LUCD) with a Buy and lowers the price target from $3 to $2.